drugset / Trial / NCT00330200

Effects of ISIS 113715 on Insulin Sensitivity, Glucose, and Lipid Metabolism and Energy Expenditure in Type 2 Diabetics

NCT00330200 ↗

Phase 2 Terminated 2 enrolled Ionis Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study is to examine the effects of ISIS 113715 monotherapy on insulin sensitivity, glucose and lipid metabolism and energy expenditure in subjects with type 2 diabetes mellitus.

Timeline

Start
2005-11-01
Primary completion
2007-03-01
Completion
2007-03-01

Outcome

Outcome not reported

Stopped (Enrollment): “Due to poor enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject ISIS 113715 Antisense oligonucleotide — —